Amgen (AMGN) Tops Q2 EPS by 14c, Raises FY Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $2.57, $0.14 better than the analyst estimate of $2.43. Revenue for the quarter came in at $5.37 billion versus the consensus estimate of $5.32 billion.

Second Quarter 2015 Product Sales Performance

Total product sales increased 6 percent for the second quarter of 2015 versus the second quarter of 2014. The increase was driven primarily by ENBREL, Prolia, Sensipar, Kyprolis and XGEVA. Growth for the quarter was due to price and higher unit demand.

• Neulasta® (pegfilgrastim) sales increased 2 percent year-over-year driven by price.NEUPOGEN® (filgrastim) sales decreased 14 percent year-over-year driven primarily by the impact of competition in the United States (U.S.).
• ENBREL sales increased 8 percent year-over-year driven by price, offset partially by the impact of competition.
• Prolia sales increased 29 percent year-over-year driven by higher unit demand.
• XGEVA sales increased 11 percent year-over-year driven primarily by higher unit demand.
• EPOGEN® (epoetin alfa) sales decreased 4 percent year-over-year driven primarily by a shift in dialysis customer purchases to Aranesp® (darbepoetin alfa), as well as the impact of competition, offset partially by price.
• Aranesp sales decreased 7 percent year-over-year driven by unfavorable changes in foreign exchange rates and a prior year positive Medicaid rebate estimate adjustment, offset partially by higher unit demand, including the shift from EPOGEN.
• Sensipar/Mimpara® sales increased 15 percent year-over-year driven by higher unit demand and price.
• Vectibix® (panitumumab) sales increased 21 percent year-over-year driven by higher unit demand.
• Nplate® (romiplostim) sales increased 6 percent year-over-year driven primarily by higher unit demand.
• Kyprolis sales increased 53 percent year-over-year driven by higher unit demand.

Amgen sees FY2015 EPS of $9.55-$9.80, versus the consensus of $9.62. Amgen sees FY2015 revenue of $21.1-21.4 billion, versus prior guidance of $20.9-21.3 million and the consensus of $21.17 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Boston Scientific (BSX) Tops Q1 EPS by 5c; Guides Above Views
• Hasbro (HAS) Tops Q1 EPS by 33c, offers guidance
• Pacific Premier Bancorp (PPBI) Tops Q1 EPS by 2c